VMD — Viemed Healthcare, Inc.

Summary of Viemed Healthcare, Inc. Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 Revenue: $76.2 million, up 26% year-over-year.
• Full Year Revenue: $270.3 million, a 21% increase compared to 2024.
• Adjusted EBITDA: Q4 totaled $18.2 million; full year reached a record $61.4 million, maintaining a margin of approximately 22.7%.
• Free Cash Flow: $28.1 million for the year, more than doubling from $11.6 million in 2024; Q4 free cash flow was $10.8 million.
• Gross Margin: Just under 58% for the year, stable despite revenue diversification.

2. Strategic Updates and Business Highlights

• Diversification: The company is evolving into a cash-generating home care platform with multiple growth engines, notably in sleep and maternal health.
• Employee Growth: Ended 2025 with 1,382 employees, focusing on building a disciplined workforce and talent pipelines.
• Maternal Health Expansion: The acquisition of Lehan’s Medical Equipment has been accretive, contributing approximately $9 million in revenue and providing a pathway for future growth.
• Ventilator Market: Despite some moderation in patient growth due to regulatory changes, the company is confident in its long-term opportunities, supported by a strong compliance framework and improved patient qualification rates under new Medicare criteria.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected to be between $310 million and $320 million, representing a 17% year-over-year growth at the midpoint.
• Adjusted EBITDA Guidance: Projected between $65 million and $69 million, with anticipated stable margins.
• Quarterly Growth Expectations: Initial flat to slightly down growth in Q1, followed by a return to normalized growth patterns in subsequent quarters, with expected sequential growth of 3% to 5%.

4. Bad News, Challenges, or Points of Concern

• Regulatory Headwinds: The transition to new documentation requirements under the National Coverage Determination (NCD) has caused short-term friction and uncertainty in the ventilator market.
• Patient Growth Moderation: There was a noted slowdown in ventilator patient growth, which the company anticipated but still poses a challenge.
• Sequential Decline in Respiratory Therapists: A reduction in the number of respiratory therapists could impact service revenue in 2026, although management expects this to stabilize with patient volumes.

5. Notable Q&A Insights

• Expansion Priorities: The focus post-Lehan acquisition includes expanding payer networks and enhancing sales force capabilities to support growth in maternal health.
• Sales Force Training: Cross-training of sales representatives is underway to leverage existing relationships and improve sales effectiveness.
• Margin Stability: Management indicated that while diversification may affect margins, operational efficiencies and technology investments are expected to help maintain stable margins.
• Patient Volume Management: The number of respiratory therapists is adjusted based on patient volumes, with expectations for growth in 2026 as the market stabilizes.

Overall, Viemed Healthcare, Inc. demonstrated strong financial performance in 2025, with a positive outlook for 2026 despite facing regulatory challenges and a need to manage workforce levels effectively.